CD8A and neoplasm: In this study, the treatment with VIC-008 was found to increase mesothelin-specific CD8+ T cell responses, to promote lymphocytic infiltration in the tumor microenvironment, but also to induce an increased expression of PD-1 in intratumoral CD8+ T lymphocytes.